“We are extremely pleased to welcome David to the Histogenics’ Board of Directors,” said Adam Gridley, president and CEO of Histogenics. “David’s financial and industry expertise and experience make him an excellent choice for Histogenics as both a board member and Chairman of the Audit Committee.”
Mr. Gill joined EndoChoice as CFO in 2014. He has held the CFO position with a number of other organizations including INC Research and TransEnterix.
Histogenics focuses on regenerative medicine in the musculoskeletal marketplace.
More articles on gastroenterology:
5 must-reads for independent GI practices
8 gastroenterologist inventors
pCLE effective at diagnosing biliary cancer patients during ERCP, study says
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
